Published in Gut on October 01, 2003
Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut (2005) 2.20
Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group. Digestion (2009) 1.19
Translational medicine: can it really facilitate the transition of research "from bench to bedside"? Eur J Clin Pharmacol (2005) 1.18
Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov (2009) 1.01
Effect of omeprazole on symptoms and ultrastructural esophageal damage in acid bile reflux. World J Gastroenterol (2005) 0.93
The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled? J Neurogastroenterol Motil (2010) 0.92
Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation. Nat Rev Gastroenterol Hepatol (2011) 0.91
A one-year follow-up study of endoluminal gastroplication (Endocinch) in GERD patients refractory to proton pump inhibitor therapy. Dig Dis Sci (2005) 0.90
Modern medical and surgical management of difficult-to-treat GORD. United European Gastroenterol J (2013) 0.89
Ambulatory reflux monitoring in GERD--which test should be performed and should therapy be stopped? Curr Gastroenterol Rep (2013) 0.88
Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig Dis Sci (2007) 0.88
Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol (2008) 0.85
Management of the patient with incomplete response to PPI therapy. Best Pract Res Clin Gastroenterol (2013) 0.82
Duodenogastric Reflux-induced (Alkaline) Esophagitis. Curr Treat Options Gastroenterol (2004) 0.81
Current pharmacological management of gastroesophageal reflux disease. Gastroenterol Res Pract (2013) 0.80
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol (2016) 0.79
The role of GABA(A) receptors in the control of transient lower oesophageal sphincter relaxations in the dog. Br J Pharmacol (2008) 0.79
Impedance-pH monitoring in proton pump inhibitor resistant patients: ready for clinical application? Gut (2006) 0.78
Current and emerging therapies for the management of functional gastrointestinal disorders. Ther Adv Chronic Dis (2011) 0.78
Neuro-regulation of lower esophageal sphincter function as treatment for gastroesophageal reflux disease. World J Gastroenterol (2008) 0.78
Nocturnal gastroesophageal reflux revisited by impedance-pH monitoring. J Neurogastroenterol Motil (2011) 0.78
Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol (2016) 0.77
Effects of (2R)-(3-amino-2-fluoropropyl)sulphinic acid (AFPSiA) on transient lower oesophageal sphincter relaxation in dogs and mechanism of hypothermic effects in mice. Br J Pharmacol (2005) 0.77
The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract (2014) 0.76
Ambulatory pH Monitoring: New Advances and Indications. Gastroenterol Hepatol (N Y) (2006) 0.75
Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study. BMC Gastroenterol (2014) 0.75
Does Cholecystectomy Increase the Esophageal Alkaline Reflux? Evaluation by Impedance-pH Technique. J Neurogastroenterol Motil (2012) 0.75
A weakly acidic solution containing deoxycholic acid induces esophageal epithelial apoptosis and impairs integrity in an in vivo perfusion rabbit model. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum. Clin Transl Gastroenterol (2015) 0.75
The Regulatory Effects of Lateral Hypothalamus Area GABAB Receptor on Gastric Ischemia-Reperfusion Injury in Rats. Front Physiol (2017) 0.75
Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. Dig Dis Sci (2017) 0.75
Influence of GABA-B Agonist Baclofen on Capsaicin-Induced Excitation of Secondary Peristalsis in Humans. Clin Transl Gastroenterol (2017) 0.75
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology (2000) 5.40
Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med (1982) 5.07
Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology (1994) 3.89
Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology (1988) 3.51
Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology (2001) 3.35
Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology (1995) 2.53
Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion (1992) 2.40
A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology (1991) 2.25
Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol (2004) 2.14
Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med (1995) 1.97
Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology (2000) 1.86
Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut (1996) 1.71
Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol (2001) 1.70
Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg (1999) 1.69
The extent of duodenogastric reflux in gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol (2001) 1.56
Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Am J Gastroenterol (2001) 1.47
Motor events underlying gastro-oesophageal reflux in ambulant patients with reflux oesophagitis. Neurogastroenterol Motil (1996) 1.38
Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. Gut (1998) 1.13
Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther (1990) 1.04
Sleep and nocturnal acid reflux in normal subjects and patients with reflux oesophagitis. Gut (1991) 1.02
Duodenogastroesophageal reflux and esophageal mucosal injury in mechanically ventilated patients. Gastroenterology (1999) 0.99
Site of action of GABA(B) receptor for vagal motor control of the lower esophageal sphincter in ferrets and rats. Gastroenterology (2001) 0.95
Dietary restrictions during ambulatory monitoring of duodenogastroesophageal reflux. Dig Dis Sci (2003) 0.90
Analysis of ambulatory duodenogastroesophageal reflux monitoring. Dig Dis Sci (2000) 0.89
Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. Dig Dis Sci (1996) 0.86
Medical treatment of gastroesophageal reflux disease - beyond the proton pump inhibitors. Dig Dis (2000) 0.84
Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor. Dig Dis Sci (1995) 0.84
U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci (1993) 7.98
Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology (1998) 5.34
The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest (1977) 3.89
Is lung cancer associated with asbestos exposure when there are no small opacities on the chest radiograph? Lancet (1995) 3.59
The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther (2003) 3.41
Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med (1990) 2.67
Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther (2011) 2.42
Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology (2001) 2.41
Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology (2001) 2.36
A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut (2006) 2.33
Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther (2003) 2.28
Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut (2005) 2.20
To dilate or to operate? That is the question. Gut (1983) 2.16
Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol (2004) 2.14
Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut (2007) 2.11
Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut (2008) 2.00
Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer. Gut (1980) 1.95
Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr (1992) 1.89
Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2003) 1.82
Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut (2005) 1.82
Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res (2004) 1.76
24-hour recording of esophageal pressure and pH in patients with noncardiac chest pain. Gastroenterology (1986) 1.75
Management of heartburn not responding to proton pump inhibitors. Gut (2009) 1.75
Achalasia, diffuse esophageal spasm, and related motility disorders. Gastroenterology (1979) 1.73
Motilin and the interdigestive migrating motor complex in man. Dig Dis Sci (1979) 1.67
Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut (2008) 1.67
Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus. Gut (2007) 1.66
The irritable oesophagus--a frequent cause of angina-like pain. Lancet (1987) 1.65
Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology (1992) 1.62
Relevance of ineffective oesophageal motility during oesophageal acid clearance. Gut (2003) 1.61
Capillary electrophoresis system for hemoglobin A1c determinations evaluated. Clin Chem (1997) 1.61
Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut (2005) 1.60
Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones. Neurogastroenterol Motil (2009) 1.59
Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther (2005) 1.57
Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2011) 1.56
Ambulatory gastrojejunal manometry in severe motility-like dyspepsia: lack of correlation between dysmotility, symptoms, and gastric emptying. Gut (1998) 1.54
Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J (2007) 1.52
Associations between gastric sensorimotor function, depression, somatization, and symptom-based subgroups in functional gastroduodenal disorders: are all symptoms equal? Neurogastroenterol Motil (2012) 1.51
Assessment of gastric sensorimotor function in paediatric patients with unexplained dyspeptic symptoms and poor weight gain. Neurogastroenterol Motil (2007) 1.50
Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther (2012) 1.48
Ambulatory 24 hour intraoesophageal pH and pressure recordings v provocation tests in the diagnosis of chest pain of oesophageal origin. Gut (1990) 1.48
Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Am J Gastroenterol (2001) 1.47
Failing deglutitive inhibition in primary esophageal motility disorders. Gastroenterology (1994) 1.47
Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry (2010) 1.46
Pulmonary sequestration: a comparison between pediatric and adult patients. Eur J Cardiothorac Surg (2001) 1.46
Different regional brain activity during physiological gastric distension compared to balloon distension: a H2 15O-PET study. Neurogastroenterol Motil (2010) 1.45
Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia. Gut (2003) 1.44
Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms. Aliment Pharmacol Ther (2007) 1.44
Aerophagia, gastric, and supragastric belching: a study using intraluminal electrical impedance monitoring. Gut (2004) 1.43
Multiple rapid swallowing: a complementary test during standard oesophageal manometry. Neurogastroenterol Motil (2009) 1.43
The secretory component of the interdigestive migrating motor complex in man. Scand J Gastroenterol (1979) 1.41
Pneumatic dilation for achalasia--the way forward. Aliment Pharmacol Ther (2011) 1.40
Perception of dysphagia: lack of correlation with objective measurements of esophageal function. Neurogastroenterol Motil (2010) 1.40
Extraoesophageal manifestations of gastro-oesophageal reflux. Gut (2005) 1.40
A wave of inhibition precedes primary peristaltic contractions in the human esophagus. Gastroenterology (1992) 1.40
Controlled trial of YAG laser treatment of upper digestive hemorrhage. Gastroenterology (1982) 1.39
Comparison of endoscopic polidocanol injection and YAG laser therapy for bleeding peptic ulcers. Lancet (1989) 1.38
Sleeve lobectomy for non-small cell lung cancer. Acta Chir Belg (2004) 1.37
Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut (2000) 1.34
Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther (2005) 1.34
Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology (1992) 1.33
Fasting plasma motilin levels are related to the interdigestive motility complex. Gastroenterology (1980) 1.32
Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut (2005) 1.32
Impaired gastric accommodation and its role in dyspepsia. Gut (2006) 1.31
Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil (2009) 1.27
Functional esophageal disorders. Gut (1999) 1.26
Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther (2007) 1.24
Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut (1998) 1.24
The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol (2001) 1.23
Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther (2012) 1.22
Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquids. J Nucl Med (1990) 1.22
Improved diagnosis of gastro-oesophageal reflux in patients with unexplained chronic cough. Aliment Pharmacol Ther (2007) 1.21
Urinary and faecal incontinence in community-residing elderly women. Age Ageing (1992) 1.20
Predictors of the placebo response in functional dyspepsia. Aliment Pharmacol Ther (2006) 1.20
Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group. Digestion (2009) 1.19